Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
The plant is scheduled to come on stream in September 2024
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers
Digital meetings driving international partnering at CPhI Japan as companies search for ingredients suppliers
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
